<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254978</url>
  </required_header>
  <id_info>
    <org_study_id>IMG-7289-CTP-201</org_study_id>
    <nct_id>NCT04254978</nct_id>
  </id_info>
  <brief_title>IMG-7289 in Patients With Essential Thrombocythemia</brief_title>
  <official_title>A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imago BioSciences,Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imago BioSciences,Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in&#xD;
      patients with essential thrombocythemia.&#xD;
&#xD;
      This study investigates the following:&#xD;
&#xD;
        -  The safety and tolerability of IMG-7289&#xD;
&#xD;
        -  The pharmacodynamic effect of IMG-7289&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and&#xD;
      pharmacodynamics of IMG-7289 administered orally once daily in patients with essential&#xD;
      thrombocythemia (ET). Patients will be dosed with IMG-7289 for 169 consecutive days in the&#xD;
      Initial Treatment Period (ITP). Qualifying patients may continue to receive IMG-7289 in the&#xD;
      Additional Treatment Period (ATP).&#xD;
&#xD;
      Safety will be evaluated by clinical assessments of safety parameters i.e. safety laboratory&#xD;
      testing, adverse event reporting, physical examination and vital sign assessments.&#xD;
      Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden,&#xD;
      change in spleen size by palpation and other measures.&#xD;
&#xD;
      To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters&#xD;
      and pharmacodynamic markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-center, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of IMG-7289 when administered to patients with essential thrombocythemia</measure>
    <time_frame>Assessed from the time of first dose through 14 days after end of treatment.</time_frame>
    <description>Safety measured by incidence and severity of treatment-emergent adverse events (using CTCAE), and changes in physical examination including vital signs, and hematology, coagulation, chemistry and urinalysis laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The efficacy of IMG-7289 when administered to patients with essential thrombocythemia</measure>
    <time_frame>Assessed serially at each visit from time of first dose through 14 days after end of treatment</time_frame>
    <description>Change in platelet counts to the protocol defined target threshold, in the absence of new thromboembolic events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>IMG-7289</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMG-7289 administered daily for 169 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMG-7289</intervention_name>
    <description>LSD1 inhibitor</description>
    <arm_group_label>IMG-7289</arm_group_label>
    <other_name>bomedemstat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic&#xD;
             criteria for myeloproliferative neoplasms.&#xD;
&#xD;
          -  Requires treatment in order to lower platelet count based on patient age over 60 or&#xD;
             history of thrombosis.&#xD;
&#xD;
          -  Have failed at least one standard therapy&#xD;
&#xD;
          -  Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to&#xD;
             study drug initiation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered&#xD;
             from side effects of such surgery.&#xD;
&#xD;
          -  Unresolved treatment related toxicities from prior therapies (unless resolved to ≤&#xD;
             Grade 1).&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Current use of prohibited medications&#xD;
&#xD;
          -  Known HIV infection or active Hepatitis B or Hepatitis C virus infection&#xD;
&#xD;
          -  Other hematologic/biochemistry requirements, as per protocol&#xD;
&#xD;
          -  Use of investigational agent within last 14 days&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Rienhoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imago BioSciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Peppe</last_name>
    <phone>1-415-529-5055</phone>
    <email>jennifer.peppe@imagobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amber Jones</last_name>
    <email>amber.jones@imagobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trinity Samson</last_name>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hoare</last_name>
      <email>christine.hoare@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Göthert</last_name>
      <email>joachim.goethert@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Paoli</last_name>
      <email>CRIMM@aou-careggi.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Seto</last_name>
      <email>Katie.Seto@mmclintrials.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Harrison</last_name>
      <email>Claire.Harrison@gstt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

